Ohio Public Employees Retirement System (OPERS)
LCTX icon

Ohio Public Employees Retirement System (OPERS)’s Lineage Cell Therapeutics LCTX Stock Holding History

Ohio Public Employees Retirement System (OPERS)’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-45,623
Closed -$52K – 1980
2022
Q3 		$52K Buy
+45,623
New +$67K ﹤0.01% 1838

Other funds holding LCTX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
PGP
Prescott General Partners Boca Raton, Florida $1.37B AUM 23.81% 1-Year Est. Return
RA
Raffles Associates New York $115M AUM 35.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Ohio Public Employees Retirement System (OPERS)'s LCTX Position: Q4 2022 in Review

Ohio Public Employees Retirement System (OPERS) sold out of Lineage Cell Therapeutics (LCTX) in Q4 2022, closing a stake of 45,623 shares — an estimated $52K sold.

Ohio Public Employees Retirement System (OPERS) first reported a position in LCTX in Q3 2022 and held it in 1 quarter. The position peaked at $52K in Q3 2022. 106 funds tracked by Wall St. Rank hold LCTX as of Q4 2022.

  • Ohio Public Employees Retirement System (OPERS) reported no remaining Lineage Cell Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Ohio Public Employees Retirement System (OPERS) sold 45,623 Lineage Cell Therapeutics shares in Q4 2022, an estimated $52K.
  • Ohio Public Employees Retirement System (OPERS) first reported a position in Lineage Cell Therapeutics in Q3 2022 and held it in 1 quarter.
  • Ohio Public Employees Retirement System (OPERS)'s Lineage Cell Therapeutics position peaked at $52K in Q3 2022.
  • 106 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q4 2022.

Based on Ohio Public Employees Retirement System (OPERS)'s 13F filing for Q4 2022, filed 15 Feb 2023.